ACLX241115P75000
- 0.40
- -1.80-81.82%
Arcellx Newsroom
Morgan Stanley Adjusts Arcellx's Price Target to $106 From $81, Keeps Overweight Rating
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $91 to $106
Arcellx Inc (ACLX) Gets a Buy From Scotiabank
Arcellx Is Maintained at Outperform by Baird
Arcellx Analyst Ratings
Promising Efficacy and Safety Profile of Arcellx Inc's IMMagine-1 Trial Leads to Buy Rating
Stifel Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $122
Truist Financial Maintains Arcellx(ACLX.US) With Buy Rating
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121
Needham Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $96
Evercore Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $120
William Blair Maintains Arcellx(ACLX.US) With Buy Rating
Arcellx Inc's Anito-cel Therapy Gains 'Buy' Rating Amid Promising IMMagine-1 Study Data and Safety Profile
Stifel Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $122
Arcellx Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $121
Arcellx Initiated With a Buy at Redburn Atlantic
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85